GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kitazato 368A.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

1,268

+1.60%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Kitazato

Its shares trade on Tokyo Stock Exchange under the ticker 368A.T. It has been listed since 25 June 2025. In the fiscal year to 31 March 2025, it reported revenue of ¥10.30bn and net income of ¥3.79bn. At that date it held total assets of ¥19.75bn and shareholders' equity of ¥18.25bn.

Kitazato Corp. engages in the manufacturing and sale of medical devices, reagents and related products for infertility treatment. The company is headquartered in Fuji-Shi, Shizuoka-Ken. The company went IPO on 2025-06-25. The firm specializes in reproductive engineering technology in artificial insemination, in vitro fertilization, cell cryopreservation, and regenerative medicine, and manufactures and sells consumables such as medical equipment and reagents that support infertility treatment. The products are mainly research reagents and medical equipment used in vitro fertilization and intracytoplasmic sperm injection. Medical devices related to infertility treatment are divided into media, cryo devices, medical devices, and micro tools. The firm is also involved in the manufacture and sale of medical equipment parts, genetic testing, sale of medical equipment for the elderly, market research and acquisition of local licenses, and contract management of living cells. The company distributes products to markets around the world, including Japan, Europe, the United States, China, and India.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
25 Jun 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Specializes in reproductive engineering technology for infertility treatment
  • Manufactures and sells consumables supporting in vitro fertilization and artificial insemination
  • Distributes products globally including Japan, Europe, the US, China, and India

Weaknesses

  • IPO date is in the future (2025-06-25)
  • No specific financial data provided for performance evaluation
  • Untrusted source description may contain inaccurate information

Opportunities

  • Growth potential in global markets for infertility treatment products
  • Expansion into regenerative medicine and genetic testing services
  • Potential for increased market share in reproductive engineering technology

Threats

  • Future IPO may face market volatility
  • Reliance on untrusted source for factual information
  • Competition in the global medical device market

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.